4,700 Shares in Tempus AI, Inc. $TEM Purchased by Cladis Investment Advisory LLC

Key Points

• Cladis Investment Advisory LLC has invested approximately $227,000 in Tempus AI, acquiring 4,700 shares during the first quarter.
• Tempus AI reported a quarterly revenue of $314.64 million, exceeding analyst expectations and showing an 89.5% year-over-year increase.
• Recent insider activity saw director Theodore Leonsis and EVP Erik Phelps sell shares of Tempus AI, with over 802,000 shares sold worth around $54 million in the last quarter.

Cladis Investment Advisory LLC purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 4,700 shares of the company's stock, valued at approximately $227,000.

Other large investors have also added to or reduced their stakes in the company. Cherry Tree Wealth Management LLC purchased a new stake in Tempus AI during the 1st quarter valued at about $31,000. University of Texas Texas AM Investment Management Co. purchased a new stake in Tempus AI during the 1st quarter valued at about $33,000. Bartlett & CO. Wealth Management LLC grew its stake in Tempus AI by 100.0% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company's stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Nemes Rush Group LLC purchased a new stake in Tempus AI during the 1st quarter valued at about $39,000. Finally, Continuum Advisory LLC purchased a new stake in Tempus AI during the 1st quarter valued at about $39,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Tempus AI Price Performance

NASDAQ TEM traded down $5.37 on Tuesday, hitting $73.08. The company had a trading volume of 12,658,702 shares, compared to its average volume of 10,771,664. The company has a market capitalization of $12.70 billion, a PE ratio of -61.41 and a beta of 4.98. The company's fifty day moving average price is $63.43 and its 200-day moving average price is $58.88. The company has a debt-to-equity ratio of 2.58, a current ratio of 1.54 and a quick ratio of 1.43. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $91.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $314.64 million during the quarter, compared to analyst estimates of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The firm's revenue was up 89.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. As a group, analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $62.87, for a total value of $10,452,137.50. Following the sale, the chief executive officer directly owned 9,274,033 shares in the company, valued at approximately $583,058,454.71. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore Leonsis sold 44,000 shares of Tempus AI stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $69.90, for a total value of $3,075,600.00. Following the completion of the sale, the director owned 86,756 shares in the company, valued at approximately $6,064,244.40. The trade was a 33.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 723,039 shares of company stock worth $49,035,482 in the last quarter. 27.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on TEM. Piper Sandler reiterated a "neutral" rating on shares of Tempus AI in a research note on Friday, August 8th. BTIG Research initiated coverage on Tempus AI in a report on Friday, August 8th. They issued a "buy" rating and a $60.00 price objective for the company. Morgan Stanley boosted their price objective on Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, August 12th. Guggenheim boosted their price objective on Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a report on Monday, June 30th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Tempus AI presently has an average rating of "Moderate Buy" and a consensus price target of $65.36.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.